LPCN submits Exhibit 99.1 for H.C. Wainwright investor conference
Rhea-AI Filing Summary
Lipocine Inc. filed an 8-K reporting a material event: the company submitted a presentation as Exhibit 99.1 for the H.C. Wainwright 27th Annual Global Investor Conference and included the interactive cover page Exhibit 104 in Inline XBRL format. The filing is signed by Mahesh V. Patel, President and Chief Executive Officer, and is dated September 5, 2025. The filing does not include earnings, financial tables, or other material transaction disclosures; it documents public investor-facing presentation materials being made available.
Positive
- Exhibit 99.1 presentation furnished for the H.C. Wainwright 27th Annual Global Investor Conference on September 5, 2025
- Exhibit 104 Inline XBRL cover page included, improving machine-readable disclosure
Negative
- No financial results or earnings data were included in the filing
- No material transactions or new agreements were disclosed in this 8-K
Insights
Company disclosed investor presentation materials at a major conference on September 5, 2025.
The filing registers that a presentation (Exhibit 99.1) for the H.C. Wainwright 27th Annual Global Investor Conference was furnished and that the Inline XBRL cover page (Exhibit 104) was included. This formalizes public dissemination of slides or remarks to investors and satisfies SEC exhibit furnishing requirements.
Because no financial results, guidance, or material agreements were attached, the immediate investor impact is limited to increased disclosure access; monitor any subsequent filings or slide content for new program, clinical, or timeline details over the following weeks.
8-K confirms compliance steps for written communications and exhibit submission.
The submission includes the specified exhibits and a CEO signature, indicating procedural compliance with reporting obligations for investor communications. The form notes checkboxes for solicitation and pre-commencement communications but none are marked, clarifying the nature of the disclosure.
Investors should note that this filing documents disclosure mechanics rather than operational changes; any material developments referenced in the presentation would need their own filings to be separately material and actionable.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
Commission
File No.
(State or other jurisdiction of incorporation) |
(IRS Employer Identification Number) |
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
Former name or former address, if changed since last report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13©(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events |
The Company is presenting and meeting with investors at the H.C. Wainwright 27th Annual Global Investor Conference September 8-10, 2025, in New York City, New York. A copy of the presentation is furnished as Exhibit 99.1 to this report and incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
The following exhibits are filed with this report:
| Exhibit No. | Description | |
| 99.1 | Presentation for the H.C. Wainwright 27th Annual Global Investor Conference | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LIPOCINE INC. | ||||
| Date: | September 5, 2025 | By: | /s/ Mahesh V. Patel | |
| Mahesh V. Patel | ||||
| President and Chief Executive Officer | ||||
FAQ
What did Lipocine (LPCN) disclose in the 8-K filed on September 5, 2025?
Does the 8-K include earnings or financial tables for LPCN?
Who signed the Lipocine 8-K filing?
Was solicitation or pre-commencement communication indicated in the filing?
Where can investors find the presentation referenced in the 8-K?
